Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Japan Drug Makers Should Consider Mergers, Other Deals to Survive: Chugai Chief
July 27, 2015
-
BUSINESS Toho to Differentiate Itself through Customer Support Rather than Prices: Pres.
July 24, 2015
-
ORGANIZATION Drug Pricing Tomorrow: Full Interview with Kenporen Vice President Shirakawa
July 24, 2015
-
REGULATORY Drug Pricing Organization Proposes Re-Pricing of Products with Huge Sales
July 23, 2015
-
REGULATORY Z2 Rule, DPC Incentive Need Revisions in Line with New Generic Target: MOF Budget Examiner
July 22, 2015
-
REGULATORY PAFSC’s First Committee to Discuss Actelion’s Tracleer, Other Products on July 31
July 21, 2015
-
TRENDS IFN-Free Drugs Upending Hepatitis C Market Landscape
July 17, 2015
-
BUSINESS ASCO Immunotherapy Roundup - 3: AZ Set to Harness Rich Pipeline to Pursue Combo Strategy
July 16, 2015
-
BUSINESS As 80% Era Looms, 3 Generic Majors Will Emerge as Dominant Suppliers: Sawai
July 16, 2015
-
ORGANIZATION Drug Pricing Tomorrow: Kenporen Veep Wants Holistic Drug Policy in FY2016 Reform
July 15, 2015
-
REGULATORY Drug Pricing Tomorrow: Full Interview with MHLW Economic Affairs Head Jo - Part 2
July 15, 2015
-
BUSINESS ASCO Immunotherapy Roundup - 2: Chugai Has High Hopes for Atezolizumab Combos with Group Portfolios
July 14, 2015
-
REGULATORY Govt, Pharma Leaders to Meet in August for Drafting of “Comprehensive Strategy”
July 13, 2015
-
ORGANIZATION “Humanitarian Trials” Hefty Burden on Drug Makers: JPMA Regulatory Head
July 10, 2015
-
REGULATORY MHLW to Seek “Candidate Drug Lists” for Patient-Initiated Mixed Care from Medical Societies
July 9, 2015
-
BUSINESS Sawai Gearing Up to Revise 3-Year Biz Plan after New Generic Target
July 8, 2015
-
REGULATORY Drug Pricing Tomorrow: Full Interview with MHLW Economic Affairs Head Jo - Part 1
July 8, 2015
-
BUSINESS ASCO Immunotherapy Roundup - 1: Opdivo Data Boost Confidence in BMS’s Combination Strategy
July 7, 2015
-
BUSINESS Foreign Drug Makers’ Sales Dip on Generic Inroads in 2014
July 6, 2015
-
REGULATORY NCC Eyes Trial Enrollment of 150 Rare Cancer Patients under Registry Initiative
July 3, 2015
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…